|Datasheet||Specific References||Reviews||Related Products||Protocols|
The pGEM-T is 3kb in length, and contains the amplicin resistance gene, conferring selection of the plasmid in E. coli, and the ori site which is the bacterial origin of replication. The plasmid has multiple cloning sites as shown below. The coding sequence was inserted by TA cloning. Many E. coli strains are suitable for the propagation of this vector including JM109, DH5α and TOP10.
The coding sequence can be easily obtained by digesting the vector with proper restriction enzyme(s). The coding sequence can also be amplified by PCR with M13 primers, or primer pair SP6 and T7.
|Canine IGF2 ORF mammalian expression plasmid, C-GFPSpark tag||DG70041-ACG|
|Canine IGF2 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||DG70041-ACR|
|Canine IGF2 ORF mammalian expression plasmid, C-Flag tag||DG70041-CF|
|Canine IGF2 ORF mammalian expression plasmid, C-His tag||DG70041-CH|
|Canine IGF2 ORF mammalian expression plasmid, C-Myc tag||DG70041-CM|
|Canine IGF2 ORF mammalian expression plasmid, C-HA tag||DG70041-CY|
|Canine IGF2 ORF mammalian expression plasmid, N-Flag tag||DG70041-NF|
|Canine IGF2 ORF mammalian expression plasmid, N-His tag||DG70041-NH|
|Canine IGF2 ORF mammalian expression plasmid, N-Myc tag||DG70041-NM|
|Canine IGF2 ORF mammalian expression plasmid, N-HA tag||DG70041-NY|
|Canine IGF2 natural ORF mammalian expression plasmid||DG70041-UT|
|Learn more about expression Vectors|
Insulin-like growth factor 2 (IGF-2/IGF-II) is a member of the insulin family of polypeptide growth factors, which are involved in development and growth. It is an imprinted gene, expressed only from the paternal allele, and epigenetic changes at this locus are associated with Wilms tumour, Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-Russell syndrome. IGF-2/IGF-II is a mediator of prolactin-induced alveologenesis; prolactin, IGF-2, and cyclin D1, all of which are overexpressed in breast cancers, are components of a developmental pathway in the mammary gland. IGF-2 and exhibited statistically significant, positive associations with colorectal cancer risk when cases were confined to those diagnosed within a relatively short time period after enrolment. Circulating IGF-2 and IGFBP-3 can serve as early indicators of impending colorectal cancer. IGF-2/IGF-II appears to be involved in the progression of many tumours. It binds to at least two different types of receptor: IGF type 1 (IGF 1R) and mannose 6-phosphate/IGF type 2 (M6-P/IGF 2R). Ligand binding to IGF 1R provokes mitogenic and anti-apoptotic effects. M6-P/IGF 2R has a tumour suppressor function—it mediates IGF 2 degradation. Mutation of M6-P/IGF 2R causes both diminished growth suppression and augmented growth stimulation. The aim of this study was to investigate the role of IGF 2 and its receptors (IGF 1R and IGF 2R) in human gastric cancer.